UNSPSC 51152034: Lanperisone

This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TO2JP2G53H. European Medicines Agency schedules Lanperisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08400MIG. Lanperisone generally arises in the molecular formula C15H18F3NO.

UNSPSC 51152034 Lanperisone is a Commodity code that in recent state and local procurement activity maps to pharmaceutical products and pharmacy-related services, though the recent opportunities tagged under it diverge significantly from the code's nominal pharmaceutical-ingredient scope. Seminole County, Florida and the Texas Health and Human Services Commission have posted solicitations that fall under this code's taxonomy assignment, but the actual work being bought spans naloxone procurement, safe drug deactivation systems, and direct-to-manufacturer pharmacy benefit administration rather than the specific muscle relaxant implied by the code name. State and local issuing bodies using this code include county health departments and state health and human services commissions; the recent record shows limited issuing-body depth, with only Seminole County and Texas HHS represented in the current opportunity window.

Recent activity centers on Florida and Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a response deadline of July 26, 2023, and quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, which functions as market intelligence rather than a formal competitive solicitation. The code shows limited recent activity overall, and the mismatch between the code's nominal pharmaceutical-ingredient classification and the actual health-systems procurement being tagged suggests either miscoding by the issuing bodies or a broader UNSPSC application to pharmacy-benefit administration that differs from traditional pharmaceutical manufacturing and supply.